Cancer stem cell markers predict a poor prognosis in renal cell carcinoma: a meta-analysis.
Cancer stem cell markers predict a poor prognosis in renal cell carcinoma: a meta-analysis.
复制标题
DOI：
10.18632/oncotarget.11672
复制
发表时间：
2016-10-04
期刊：
影响因子：
--
通讯作者：
Qiu X
中科院分区：
文献类型：
--
作者：
Cheng B;Yang G;Jiang R;Cheng Y;Yang H;Pei L;Qiu X
肿瘤干细胞相关标志物可作为肾细胞癌预后的生物标志物。然而，它们的实际预后意义仍然没有定论。因此，进行荟萃分析以更准确地重新评估CSC相关标志物（CXCR 4、CD 133、CD 44、CD 105）表达与RCC预后的相关性。检索PubMed和Embase以寻找合格的研究。合并的风险比（HR）和95%置信区间（95%CI）用于重新评估CSC标志物表达与RCC预后（总生存期（OS）、癌症特异性生存期（CSS）、无病生存期（DFS）和无进展生存期（PFS））的相关性。共有25篇相关文章，包括2673例RCC患者，符合荟萃分析的条件。总体汇总分析表明，高CSC标志物表达预测OS（HR，2.10，95% CI：1.73-2.55）和DFS（HR，3.77，95% CI：2.30-6.19）较差。CXCR 4高表达预示OS（HR，2.57，95%CI：1.95-3.40）、CSS（HR，1.97，95%CI：1.50-2.59）和DFS（HR，5.82，95%CI：3.01-11.25）较差。在RCC患者中，CD 44过表达与OS（HR，1.58，95%CI：1.14-2.18）、CSS（HR，2.58，95%CI：1.27-5.23）和DFS（HR，4.49，95%CI：2.12-9.53）差相关。CD 133是CSS的独立预后因素（HR，0.4，95%CI：0.29-0.54）。CSC标志物的存在与RCC预后不良相关。CSC可能被潜在地用作RCC患者分层的预后标志物，也可能代表新的潜在治疗靶点。
Relevant markers of CSCs may serve as prognostic biomarkers of RCC. However, their actual prognostic significance remains inconclusive. Thus, a meta-analysis was performed to reevaluate the association of CSCs-relevant markers (CXCR4, CD133, CD44, CD105) expression with RCC prognosis more precisely. PubMed and Embase were searched to look for eligible studies. The pooled hazard ratios (HR) with 95% confidence intervals (95% CI) were used to reassess the association of CSCs markers expression and RCC prognosis of overall survival (OS), cancer-specific survival (CSS), disease-free survival (DFS), and progression-free survival (PFS). There were 25 relevant articles, encompassing 2673 RCC patients, eligible for meta-analysis. Overall pooled analysis suggested that high CSCs markers expression predicted poor OS (HR, 2.10, 95% CI: 1.73–2.55) and DFS (HR, 3.77, 95% CI: 2.30–6.19). High CXCR4 expression predicted worse OS (HR, 2.57, 95% CI: 1.95–3.40), CSS (HR,1.97, 95% CI: 1.50–2.59), and DFS (HR, 5.82, 95% CI: 3.01–11.25). CD44 over-expression correlated with a poor OS(HR,1.58, 95% CI: 1.14–2.18), CSS (HR, 2.58, 95% CI: 1.27–5.23), and DFS (HR, 4.49, 95% CI: 2.12–9.53) in RCC patients. CD133 was an independent favorable prognostic factor for CSS (HR, 0.4, 95% CI: 0.29–0.54). The presence of CSCs markers correlates with poor RCC outcome. CSCs may be potentially utilized as prognostic markers to stratify RCC patients, probably representing also a novel potential therapeutic target.